Zhongguancun Successfully Developed the World's First Defective Gene Chip

“Our children are very likely to have normal hearing in the future.” This is a newly-married couple in Chaoyang District. The two of them had been deaf and very much wanted children, but they were also worried about inheriting their deafness to their children. After a new test called "Genetic Screening for Genotyping" confirmed that the deafness genes of the two were different, it gave them hope for a healthy baby.

The process of “generating genetic screening for delirium” is very simple. Take a few drops of blood on a nail-sized biochip and find the deafness gene after 6 hours. This gene chip for the detection of hereditary deafness was developed by Zhongguancun Boao Biotech Co., Ltd. and is the world's first gene chip for caries detection in clinical practice.

Beijing has included the “general screening of genetic markers for high-risk groups” in the “2011 municipal government’s practical projects for private citizens”. The government has purchased services and has provided free testing for more than 20,000 certified hearing impaired people. At present, 20,839 deaf people in 16 districts and counties have been screened for cariogenicity. The screening rate has reached 96.3%, and 2970 people have detected carcinogenic mutations. "This group has a high prevalence of hereditary deafness and a high probability of having deaf children with offspring." Professor Dai Pu of the People's Liberation Army General Hospital who participated in the project said that when deaf people love to marry, they should pay attention to the color of their test results cards and find themselves. People with different card colors will have a much lower risk of having deaf children.

Prior to the introduction of biochips by BioBio, the hospital had no routine genetic testing program for deafness. Detection of deafness genes requires genome sequencing, which is costly.

Although the hereditary deafness gene detection chip has a large nail size and the market price is only a few hundred dollars, it can simultaneously detect nine genetic loci related to dental caries, such as severe congenital deafness and drug deafness. Deafness gene screening can identify the cause of deafness as soon as possible, take early intervention and reduce the risk of deaf children.

In Haidian District, a monk who had been pregnant for 4 months came to test and hoped that the fetus in her abdomen would avoid tragedy. The test results showed that she carried the mitochondrial mutation gene, also called a needle-induced gene. "The drug-induced deafness carriers are sensitive to dozens of aminoglycoside antibiotics such as streptomycin. If one antibiotic is given, it will cause delirium. However, as long as such sensitive drugs are not injected, deafness can be avoided. Cheng Jing, academician of the Chinese Academy of Engineering and director of biotechnology at Boao said.

The drug-induced deafness gene is maternally inherited. If a woman has a deafness gene, her mother, siblings, and her children all carry the gene. When she was born, a boy would cause her to be paralyzed. The third generation would not inherit this gene. But if she was a girl, not only would the injections cause embarrassment, but her offspring would continue to inherit. “The project team passed a deaf man who came to the screening process and discovered that more than 10 people in his family carry the gene. Although some people have normal hearing, they must pay attention to safe medication.” Zhao Zhixian, director of biological marketing, said that biochips allow one person to test multiple people to benefit, even benefit a few.

Biochip, combined with biopharmaceutical detection technology and microelectronics technology, orderly combines nucleic acids or protein fragments on a small substrate and reacts the sample to be tested with nucleic acid or protein on the chip to analyze the samples to be examined. The corresponding ingredients. At the end of the last century, biochips rose in the United States and Europe. Cheng Jing, the chief scientist of Nanogen, was founded in 2000 and started research and development of biochips in Zhongguancun. When SARS raged in 2003, Cheng Jing and his team spent seven days without sleep and developed a biochip for SARS virus detection. After more than 400 clinical samples were tested and analyzed, the test results were confirmed to be the most accurate. The first application of biochips in clinical applications in China shows tremendous power. Subsequently, Boao Biotechnology successfully obtained the first medical device certificate and the first foreign chip patent authorization for biochips, and successively launched more than 60 biochips, testing instruments and other products. Among them, more than ten biochips, including genetic deafness gene detection chips and cell viability electrorotation detection chips, are the world's first. US "Fortune" magazine reported that Boao Bio has "became China's first biotech company to enter the world level."